GPT and metabolic dysfunction-associated steatotic liver disease: In a randomized controlled trial, empagliflozin was demonstrated to reduce liver fat and improve alanine transaminase levels in patients with T2D and NAFLD, but this effect did not correlate with glycemic improvement or body weight reduction (78).